Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tivumecirnon
- Development stage
- Phase 2
- Lead developer
- RAPT Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Tivumecirnon is an orally available small molecule antagonist of C-C chemokine receptor type 4 (CCR4). It is designed to block the migration of regulatory T cells (Tregs) specifically into tumors without depleting Tregs throughout the body. By inhibiting CCR4-mediated recruitment of immunosuppressive Tregs to the tumor microenvironment, tivumecirnon aims to abrogate immune suppression and promote effective antitumor immune responses. This mechanism may enhance the efficacy of other cancer therapies such as checkpoint inhibitors and has shown promise in combination with pembrolizumab for various cancers including EBV-positive gastric cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and extranodal NK/T-cell lymphoma[1][2][5][6][7][8][10].
- Other names
- tivumecirnonFLX475FLX-475FLX 475
02
Targets
CCR4 (C-C Motif Chemokine Receptor 4)
Beyond the preview
Go deeper on tivumecirnon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tivumecirnon.